Obesity is associated with greater risk for unfavourable pathological features in men with low risk prostate cancer who are eligible for active surveillance, according to a study. Obese men are likely to have transition zone cancer, which is related to unfavourable pathology findings in those with very low risk prostate cancer.
The intravesical installation of Bacillus Calmette-Guerin (BCG) and mitomycin C (MMC) is a safe and effective approach to nonmuscle-invasive bladder cancer (NMIBC) following transurethral resection (TUR), a new systematic review shows.
At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).
The use of spot urine appears to be unhelpful in estimating 24-hour urinary sodium excretion at the individual level due to its poor performance with regard to misclassification, according to a recent study.
There is no significant association between urine calcium and bone mineral density in a large cohort of calcium kidney stone formers, unlike in previous small cross-sectional studies, but there is a significant inverse relationship in oestrogen-untreated kidney stone formers only.
Larotrectinib delivers durable response across diverse cancer types, including paediatric and adult cancers, according to an interim analysis of three ongoing trials presented at the ASCO 2017 Annual Meeting.
Treatment with follicle-stimulating hormone appears to improve sperm DNA fragmentation, thus increasing pregnancy rates in infertile males undergoing in-vitro fertilization, according to a study. Moreover, double strand breaks, as measured with γH2AX test, show potential for predicting reproductive outcome after the treatment.
Men with lower urinary tract symptoms (LUTS) are also found to be suffering from erectile dysfunction (ED), and studies show tadalafil 5 milligram once daily is safe and effective for the treatment of both LUTS due to benign prostate hyperplasia (BPH) plus coexisting ED.